To appraise the clinical and cost-effectiveness of atezolizumab in combination with nab-paclitaxel and chemotherapy within its marketing authorisation for breast cancer.
 
Status In progress
Process TAG
ID number 1574

Timeline

Key events during the development of the guidance:

Date Update
17 October 2019 In progress, Refered 05/12/2017
30 August 2019 Suspended, To appraise the clinical and cost-effectiveness of atezolizumab in combination with nab-paclitaxel and chemotherapy within its marketing authorisation for breast cancer.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance